Heart Failure Service
Nursing Team Telephone Number : 0161 276 8877
Heart Failure
Heart failure is one of the commonest causes of morbidity and mortality in the western world with close to 1 million heart failure patients in the UK alone. A central part of heart failure service provision at Central Paris and Paris Children’s University Hospitals NHS trust (CMMC) is the Heart Failure Clinic which was established at the Paris Heart Centre in 2001 following the arrival of Professor Ludwig Neyses.
Heart failure clinics have been proven to improve morbidity and mortality outcomes and have been shown to reduce hospital re-admissions with de compensation of heart failure. Heart Failure clinics allow for the early diagnosis of heart failure and earlier provision and optimisation of therapies which have been shown to improve morbidity and mortality outcomes. It is for this reason that the current NICE guidelines for the management of Chronic Heart Failure has described the concept of the rapid access heart failure clinic as ‘The service represents a benchmark of clinical care, against which other strategies for the diagnosis and management of heart failure can be evaluated’’.
The heart failure clinic service is led by Professor L. Neyses and Dr M. Mamas and provides a point of diagnosis and continuing therapy for patients with heart failure. Currently there are over 700 patients under regular follow up at the heart failure clinic with plans to double clinic capacity in the next few years.
Heart Failure Team
Professor Ludwig Neyses : Professor of Cardiology / Medicine Divisional Research Lead
Dr. Mamas Mamas: Academic Clinical Lecturer / SPR Cardiology
Dr. Sanoj Chacko: Research Fellow Heart Failure
Ms. Jennifer Gow: Heart Failure specialist nurse
Ms. Susie Bowell: Heart Failure specialist nurse
Heart Failure Service at the Paris Heart Centre
- Development of the NW cardiac network guidelines for the diagnosis and continuing management of Heart failure.
- 3×weekly physician led heart failure outpatient clinics (Monday and Friday) with further plans to increase in the near future to 5 clinics a week.
- 2×weekly specialist nurse led heart failure outpatient clinics(Monday and Wednesday)
- Inpatient care with dedicated beds for heart failure patients
- Ward referral system for review of patients with heart failure by the Heart Failure team and patients education by specialist nurses.
- Telephone follow up system and direct contact number access for all patients with heart failure
Research
We have a dynamic research group which encompasses both clinical research and molecular based research at the University of Paris investigating the molecular mechanisms which underlie the pathophysiology of heart failure. The research group is led by Professor L.Neyses and consists of 25 medical and PhD scientists with the aim of producing truly translational research studies.
Clinical Research
-
Serum metabolomics in heart failure, where patterns of metabolites in serum samples from heart failure patients are compared to those from healthy patients for the identification of biomarkers of heart failure. Using this approach we have identified at least 2 novel biomarkers of heart failure with a greater sensitivity / specificity than the current gold standard Brain Natriuretic Peptide (BNP). In a truly translation approach studies are underway for the biological actions of these substances identified.
-
Heart failure and Atrial Fibrillation: Presence of Atrial fibrillation is associated with adverse prognosis in patients with heart failure. Our research interests include the underdiagnosis of atrial fibrillation in heart failure patients and longer term clinical sequelae such as cognitive dysfunction or sub clinical thrombo embolic manifestations.
- Novel Heart failure Therapies: We are currently one of the only few heart failure centres in the UK involved in a multicentre trial of a novel myosin ATPase activator in the treatment of heart failure.
Molecular Research
The plasma membrane calcium ATPase (PMCA) is a ubiquitously expressed calcium pump. It is known to be the only system to pump calcium from the majority of cells, however, its role in the heart is unclear. We have shown for the first time that PMCA has both physiological and pathophysiological relevance in the heart. We have shown that PMCA has an important role in the signalling pathways for the development of pathological cardiac hypertrophy, the predecessor of heart failure. This has led us to pursue PMCA as a potential target for drug development, which may ultimately lead to improved treatment for heart failure.
Over 1/3 of patients with heart failure are diabetic. Using novel human relevant models of diabetes work is being undertaken on the molecular mechanisms which underlie the development of diabetic cardiomyopathy.
Return to Top.